Abstract

At least 7 biosimilars for adalimumab (Humira–AbbVie, Inc.) are expected to hit the market in 2023. Pharmacists may find themselves managing patients on these new prescription drugs, encouraging physicians to switch their patients, or motivating patients themselves to accept these new options.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call